CAMP TAPAWINGO AUGUST 5– 10, 2018

APPLICATIONS ARE OPEN!

Click Here To Register

Camper (ages 7-15), CIT (ages 16 & 17) and
Staff Applications (18 & Older)
are available through the same link

APPLICATIONS ARE OPEN!

All applicants registered by Friday, June 1st will be considered for camp. The system will lock you out after that day, so please complete all information prior to 12:00 Midnight on June 1st.

This year you will not have an opportunity to go back in after June 1st and make changes – all of last year’s information will automatically populate most fields with just a few that will need to be refilled.

Just like last year, information inputted into the system in automatically saved so you can start the application, log out and all of the information will be available when you return to the site later. Autosaving begins after you have passed the camp fee section of the application.

****Camp will be ending a day early this year – more information will be made available once campers are completely registered. Departure from camp will be the afternoon of Friday, Aug. 10

REGISTER NOW: UNITE 

   ( http://bit.ly/HFOWalk )

Build a team, Raise money, Compete for bragging rights!

UNITE WALK – SATURDAY JUNE 2, 2018

Join us to support the 6th annual Oregon Bleeding Disorders Walk! We will walk to raise critical funds and awareness for the bleeding disorders community. Your support is greatly appreciated! For more information, please contact:

Kathleen Anderson, Local Walk Event Manager, at 541-753-0730 or kathleen@hemophiliaoregon.org

THE WALK IS AN OPPORTUNITY TO RAISE FUNDS AND AWARENESS ABOUT BLEEDING DISORDERS AND TO SUPPORT ALL OF THE SERVICES PROVIDED BY HFO ON A YEAR-ROUND BASIS.

Newsletter

The Hemophilia Foundation of Oregon enhances the quality of life for individuals with bleeding disorders and their families through advocacy, assistance, outreach, education and research support.

RSS RSS Newsfeed

  • Spark Sees Continued Progress in Hemophilia B Gene Therapy May 23, 2018
    The overall annualized bleeding rate for all 15 participants was reduced by 98% to an annual rate of 0.2 bleeds per patient. Read more about Spark Sees Continued Progress in Hemophilia B Gene Therapy
  • Genentech Announces Positive HEMLIBRA Trial Results May 23, 2018
    In the Phase III HAVEN 3 study, patients who received HEMLIBRA prophylaxis every week or every two weeks experienced a 96% and 97% reduction in treated bleeds. Read more about Genentech Announces Positive HEMLIBRA Trial Results